Last reviewed · How we verify

Mycophenylate mofetil — Competitive Intelligence Brief

Mycophenylate mofetil (Mycophenylate mofetil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant, IMPDH inhibitor. Area: Immunology.

marketed Immunosuppressant, IMPDH inhibitor Inosine monophosphate dehydrogenase (IMPDH) type II Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Mycophenylate mofetil (Mycophenylate mofetil) — Masonic Cancer Center, University of Minnesota. Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mycophenylate mofetil TARGET Mycophenylate mofetil Masonic Cancer Center, University of Minnesota marketed Immunosuppressant, IMPDH inhibitor Inosine monophosphate dehydrogenase (IMPDH) type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant, IMPDH inhibitor class)

  1. Masonic Cancer Center, University of Minnesota · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mycophenylate mofetil — Competitive Intelligence Brief. https://druglandscape.com/ci/mycophenylate-mofetil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: